Difference between revisions of "Team:Aix-Marseille/HP/Silver"

Line 3: Line 3:
 
[[File:Tree.png|500px|right|thumb|Human Practices Development]]
 
[[File:Tree.png|500px|right|thumb|Human Practices Development]]
  
We have thought about the Human Practices from the very beginning of [[Team:Aix-Marseille/Project|'''KILL XYL''']].  
+
We have thought about the Human Practices from the very beginning of [[Team:Aix-Marseille/Project|'''KILL XYL''']]. At the beginning of the project, we drew the limits of the project and discussed the different actors that were going to be involved and affected by our scientific approach.  
At the beginning of the project we drew the limits of the project and discussed which different actors were going to be involved and affected by our scientific approach.  
+
 
This way our project could be as adapted as much as possible to the needs of society.
 
This way our project could be as adapted as much as possible to the needs of society.
  
 
Then, the more our [[Team:Aix-Marseille/Project|project]] advanced and defined itself, the more we worked on the practical side of Human Practices.  
 
Then, the more our [[Team:Aix-Marseille/Project|project]] advanced and defined itself, the more we worked on the practical side of Human Practices.  
  
First and foremost [[Team:Aix-Marseille/Safety|safety]]  is crucial in a lab.  
+
First and foremost [[Team:Aix-Marseille/Safety|safety]]  is crucial in a lab. To work in synthetic biology, we ask ourselves about the consequences of our manipulation and the safety level of each organism that we used. We also always made sure to work in the best conditions. We didn't experiment with P2 level organisms. We also wanted to make sure that our product, especially our phage-like particle, as it is a GMO, is environmentally friendly and doesn't pollute the soil or harm plants.  
To work in synthetic biology, we ask our self about the consequences of our manipulation and the safety level of each part and organisms that we used.  
+
To do so, we [[Team:Aix-Marseille/M13_test|tested]] our phages in various conditions.
We also always make sure to work with the best condition and we didn't experiment with P2 level organisms.  
+
We also wanted to make sure that our product, especially our phage-like particle as it is a GMO, is environmentally friendly and doesn't pollute the soil or harm plant.  
+
To do so, we did [[Team:Aix-Marseille/M13_test|test]] our phages in various conditions.
+
  
To integrate the olive growers and farmer’s opinions, we contacted them and did [[Team:Aix-Marseille/HP/Surveys|surveys]],  
+
To know about the olive growers and farmer’s opinions, we contacted them and did [[Team:Aix-Marseille/HP/Surveys|a survey]],  
first via the web and then in person, during  [[Team:Aix-Marseille/Engagement#Salon_des_Agricultures_de_Provence|an agricultural fair]].  
+
first via the web and then in person, during [[Team:Aix-Marseille/Engagement#Salon_des_Agricultures_de_Provence|an agricultural fair]].  
This approach helped us to figure out their needs and their thoughts, about [[Team:Aix-Marseille/Xylella_fastidiosa|''Xylella fastidiosa'']], the communication about it and acceptable treatment strategies.
+
This approach helped us to figure out their needs and their thoughts about [[Team:Aix-Marseille/Xylella_fastidiosa|''Xylella fastidiosa'']]. Then we could work accordingly to what we learned from them.
  
 
We got [[Team:Aix-Marseille/HP/Interviews|advice]] from several different experts :  [[Team:Aix-Marseille/HP/Interviews#Mireille_ANSALDI|Mireille Ansaldi]], the PI of the phage cycle and bacteria metabolism group in the LCB; [[Team:Aix-Marseille/HP/Interviews#Marie-Agn.C3.A8s_JACQUES|Marie-Agnès Jacques]], a researcher and expert on [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']], and [[Team:Aix-Marseille/HP/Interviews#Jacques_VAN_HELDEN|Jacques Van Helden]], a professor of bioinformatics at Aix-Marseille University who specializes in the analysis of regulatory sequences.
 
We got [[Team:Aix-Marseille/HP/Interviews|advice]] from several different experts :  [[Team:Aix-Marseille/HP/Interviews#Mireille_ANSALDI|Mireille Ansaldi]], the PI of the phage cycle and bacteria metabolism group in the LCB; [[Team:Aix-Marseille/HP/Interviews#Marie-Agn.C3.A8s_JACQUES|Marie-Agnès Jacques]], a researcher and expert on [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']], and [[Team:Aix-Marseille/HP/Interviews#Jacques_VAN_HELDEN|Jacques Van Helden]], a professor of bioinformatics at Aix-Marseille University who specializes in the analysis of regulatory sequences.
  
Ms. Jacques, the [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] specialist and agronomist, when we consulted her about the relevance of our project, warned us we would be affected by the legislation on GMO's and the authorization of plant treatment products.  
+
Ms Jacques, the [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] specialist and agronomist, when we consulted her about the relevance of our project, warned us we would be affected by the legislation on GMO's and the authorization of plant treatment products.  
 
We therefore began a complete study of relevant [[Team:Aix-Marseille/Legislation|french and European law]], thanks to a collaboration with the [https://2017.igem.org/Team:Evry_Paris-Saclay|Evry Paris-Saclay] team.
 
We therefore began a complete study of relevant [[Team:Aix-Marseille/Legislation|french and European law]], thanks to a collaboration with the [https://2017.igem.org/Team:Evry_Paris-Saclay|Evry Paris-Saclay] team.
 
This allowed us to see the different steps necessary to sell our product in France and in Europe.
 
This allowed us to see the different steps necessary to sell our product in France and in Europe.

Revision as of 15:58, 1 November 2017

Human Practices

Human Practices Development

We have thought about the Human Practices from the very beginning of KILL XYL. At the beginning of the project, we drew the limits of the project and discussed the different actors that were going to be involved and affected by our scientific approach. This way our project could be as adapted as much as possible to the needs of society.

Then, the more our project advanced and defined itself, the more we worked on the practical side of Human Practices.

First and foremost safety  is crucial in a lab. To work in synthetic biology, we ask ourselves about the consequences of our manipulation and the safety level of each organism that we used. We also always made sure to work in the best conditions. We didn't experiment with P2 level organisms. We also wanted to make sure that our product, especially our phage-like particle, as it is a GMO, is environmentally friendly and doesn't pollute the soil or harm plants. To do so, we tested our phages in various conditions.

To know about the olive growers and farmer’s opinions, we contacted them and did a survey, first via the web and then in person, during an agricultural fair. This approach helped us to figure out their needs and their thoughts about Xylella fastidiosa. Then we could work accordingly to what we learned from them.

We got advice from several different experts :  Mireille Ansaldi, the PI of the phage cycle and bacteria metabolism group in the LCB; Marie-Agnès Jacques, a researcher and expert on X. fastidiosa, and Jacques Van Helden, a professor of bioinformatics at Aix-Marseille University who specializes in the analysis of regulatory sequences.

Ms Jacques, the X. fastidiosa specialist and agronomist, when we consulted her about the relevance of our project, warned us we would be affected by the legislation on GMO's and the authorization of plant treatment products. We therefore began a complete study of relevant french and European law, thanks to a collaboration with the Paris-Saclay team. This allowed us to see the different steps necessary to sell our product in France and in Europe.

To sum up, our project grew entwined with the human practices from the very beginning.

  • T--Aix-Marseille--survey.pngSurvey
  • InterviewInterviews
  • LegislationLegislation
  • T--Aix-Marseille--Public.pngPublic Engagement